In community-acquired pneumonia in a patient who has received antibiotics within the past three months, which antibiotic is preferred?

• A. Fluoroquinolone
• B. Azithromycin
• C. Amoxicillin
• D. Ceftriaxone

Answer: (A)

When someone with community-acquired pneumonia has recently taken antibiotics, there’s a higher risk of infection with drug-resistant organisms, especially resistant Streptococcus pneumoniae, and sometimes organisms that aren’t covered by narrow regimens. A fluoroquinolone is favored here because it offers strong, reliable coverage of both typical CAP pathogens (including resistant pneumococcus) and atypical pathogens (like Mycoplasma and Chlamydophila) in a single agent. This broad, depthful activity helps overcome the resistance risk associated with recent antibiotic exposure and allows effective oral or IV therapy as needed.

Azithromycin alone is less reliable after recent antibiotic use due to higher chances of macrolide resistance and less robust coverage of resistant pneumococcus. Amoxicillin targets typical bacteria but misses atypicals. Ceftriaxone covers typical bacteria but does not address atypical pathogens, making it less ideal as monotherapy in this scenario.